Rare disease trials differ from those in most other therapeutic areas because the indications are more complex and involve smaller patient populations. It is essential to understand the current disease landscape, the prior research, and the competitive clinical trial environment when posi¬tioning a new clinical trial within the rare disease space. This white paper discusses strategies for accelerating rare disease clinical development by lever¬aging data in a more evidence-based approach to guide the design of a trial; to understand treat¬ment trends; and to identify the best investigators, sites, and patients.
You may also be interested in:
Blog
Winning Team: Working With a Service Dog
Fact Sheet
Pharmacogenomics in Pain Management
Pharmacogenomics in Pain Management. In the US alone there are an estimated 100 million adults suffering from chronic pain. Pharmacogenomics and…
Poster
Retrospective Analysis of the Effects of Protocol Design on Completion Rates in Phase 1 Studies in Subjects with Stable Schizophrenia
Subject attrition from randomized Schizophrenia trials is a significant problem and has been found in meta-analysis to be as high as 76% (Robinowitz…